The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.
The Evolving Clinical Management of Genitourinary Cancers Amid the COVID-19 Pandemic.
复制标题
DOI：
10.3389/fonc.2021.734963
复制
发表时间：
2021
影响因子：
4.7
通讯作者：
Kyprianou N
中科院分区：
文献类型：
--
作者：
Izadmehr S;Lundon DJ;Mohamed N;Katims A;Patel V;Eilender B;Mehrazin R;Badani KK;Sfakianos JP;Tsao CK;Wiklund P;Oh WK;Cordon-Cardo C;Tewari AK;Galsky MD;Kyprianou N
冠状病毒病- 2019 （COVID-19）是一种由严重急性呼吸综合征冠状病毒2 （SARS-CoV-2）感染引起的疾病，已成为前所未有的全球突发卫生事件，在世界各地所有年龄段的成年人中造成致命后果。癌症患者的感染率和死亡率很高，有证据表明，被诊断患有癌症和SARS-CoV-2的患者预后不良的可能性更大。由于大流行造成的临床相关变化，要么是由于时间或治疗方式的变化而导致的初级变化；或继发性，由于改变了对疾病进展或治疗结果的合作作用。然而，关于2019冠状病毒病大流行期间泌尿生殖系统癌患者临床管理的研究有限，并且对区分COVID-19的原发性或继发性影响的研究很少。在此，我们综述了GU癌患者感染SARS-CoV-2的流行病学和生物学后果，以及COVID-19对这些患者诊断和管理的影响，以及新型和创新的诊断测试、治疗和技术的使用和开发。本文还讨论了在COVID-19大流行的第一年，控制病毒的生物医学进展以及在患者旅程的各个阶段管理前列腺、膀胱、肾脏、睾丸和阴茎癌的不断变化的挑战。
Coronavirus disease–2019 (COVID-19), a disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, has become an unprecedented global health emergency, with fatal outcomes among adults of all ages throughout the world. There is a high incidence of infection and mortality among cancer patients with evidence to support that patients diagnosed with cancer and SARS-CoV-2 have an increased likelihood of a poor outcome. Clinically relevant changes imposed as a result of the pandemic, are either primary, due to changes in timing or therapeutic modality; or secondary, due to altered cooperative effects on disease progression or therapeutic outcomes. However, studies on the clinical management of patients with genitourinary cancers during the COVID-19 pandemic are limited and do little to differentiate primary or secondary impacts of COVID-19. Here, we provide a review of the epidemiology and biological consequences of SARS-CoV-2 infection in GU cancer patients as well as the impact of COVID-19 on the diagnosis and management of these patients, and the use and development of novel and innovative diagnostic tests, therapies, and technology. This article also discusses the biomedical advances to control the virus and evolving challenges in the management of prostate, bladder, kidney, testicular, and penile cancers at all stages of the patient journey during the first year of the COVID-19 pandemic.
登录
查看更多内容
SARS-COV-2血统的估计可传播和影响B.1.1.7在英国。
DOI：
10.1126/science.abg3055
发表时间：
2021-04-09
期刊：
Science (New York, N.Y.)
影响因子：
--
作者：
Davies NG;Abbott S;Barnard RC;Jarvis CI;Kucharski AJ;Munday JD;Pearson CAB;Russell TW;Tully DC;Washburne AD;Wenseleers T;Gimma A;Waites W;Wong KLM;van Zandvoort K;Silverman JD;CMMID COVID-19 Working Group;COVID-19 Genomics UK (COG-UK) Consortium;Diaz-Ordaz K;Keogh R;Eggo RM;Funk S;Jit M;Atkins KE;Edmunds WJ
通讯作者：
Edmunds WJ
影响因子：
6.2
作者：
Crispen, Paul L.;Viterbo, Rosalia;Uzzo, Robert G.
通讯作者：
Uzzo, Robert G.
DOI：
10.1056/nejmoa2035389
发表时间：
2021-02-04
期刊：
The New England journal of medicine
影响因子：
--
作者：
Baden LR;El Sahly HM;Essink B;Kotloff K;Frey S;Novak R;Diemert D;Spector SA;Rouphael N;Creech CB;McGettigan J;Khetan S;Segall N;Solis J;Brosz A;Fierro C;Schwartz H;Neuzil K;Corey L;Gilbert P;Janes H;Follmann D;Marovich M;Mascola J;Polakowski L;Ledgerwood J;Graham BS;Bennett H;Pajon R;Knightly C;Leav B;Deng W;Zhou H;Han S;Ivarsson M;Miller J;Zaks T;COVE Study Group
通讯作者：
COVE Study Group
DOI：
10.1038/s41571-021-00487-z
发表时间：
2021-05
期刊：
Nature reviews. Clinical oncology
影响因子：
--
作者：
Desai A;Gainor JF;Hegde A;Schram AM;Curigliano G;Pal S;Liu SV;Halmos B;Groisberg R;Grande E;Dragovich T;Matrana M;Agarwal N;Chawla S;Kato S;Morgan G;Kasi PM;Solomon B;Loong HH;Park H;Choueiri TK;Subbiah IM;Pemmaraju N;Subbiah V;COVID19 and Cancer Clinical Trials Working Group
通讯作者：
COVID19 and Cancer Clinical Trials Working Group
影响因子：
6.6
作者：
Chipollini, Juan;Tang, Dominic H.;Spiess, Philippe E.
通讯作者：
Spiess, Philippe E.